Department of Radiation Oncology, Virginia Commonwealth University Health System, Massey Cancer Center, Box 980058, Richmond, VA, 23298, USA.
Overlake Medical Center, Radiation Oncology, Bellevue, WA, USA.
Support Care Cancer. 2020 Feb;28(2):551-560. doi: 10.1007/s00520-019-04849-3. Epub 2019 May 12.
Insomnia and related sleep disorders are common complaints among cancer patients, and use of prescription sleep aids can be high in the treatment setting. The prevalence of sleep disturbance and prescription sleep aid use in the community-dwelling cancer survivorship population, however, remains relatively unexplored. We aim to ascertain the extent to which a cancer diagnosis is associated with sleep disturbances and prescription sleep aid use as measured in several cross sections of individuals across multiple disease sites and time since cancer diagnosis.
We used data from five cross-sectional cycles of the National Health and Nutrition Evaluation Survey (NHANES) from 2005 to 2014. We identified a total of 2371 individuals who reported a diagnosis of cancer (averaging 61 years old) and 25,788 individuals who did not report a cancer diagnosis (averaging 45 years old). We considered several patient-reported sleep-related outcomes. Multivariate regression analyses, as well as propensity score matching, were used to clarify the relationship between sleep disturbances, prescription sleep aid use, and cancer diagnosis, stratified by time since diagnosis and primary disease site.
Reported sleep disturbance was common in cancer survivors, with approximately 34% of patients with a history of cancer reporting having ever been told they had trouble sleeping, compared to 23% of non-cancer patients in the general population with no history of cancer (p < 0.001). Propensity score matching supported a significantly higher rate of trouble sleeping among cancer survivors compared to matched controls. Compared to the general adult population without cancer, cancer survivors 11 or more years past diagnosis were more likely to report being diagnosed with trouble sleeping or a sleep disorder. Further, patients with gynecological cancers were more likely to report prescription sleep aid use, sleep disorders, and trouble sleeping compared to adults without a history of cancer.
Sleeping problems are common in the cancer survivorship population, especially in patients with a long survivorship history and a history of gynecological cancers. Consideration of symptoms of insomnia and sleep disturbance may be helpful in the follow-up care of these patients.
失眠和相关睡眠障碍是癌症患者常见的抱怨,在治疗环境中使用处方助眠药物的情况较为普遍。然而,在社区居住的癌症幸存者人群中,睡眠障碍和处方助眠药物的使用的流行程度仍相对未知。我们旨在确定癌症诊断与睡眠障碍和处方助眠药物使用之间的关系程度,这些数据来自多个疾病部位和癌症诊断后时间的多个个体的几个横断面。
我们使用了 2005 年至 2014 年期间五次国家健康和营养评估调查(NHANES)的横断面数据。我们共确定了 2371 名报告癌症诊断(平均年龄 61 岁)的个体和 25788 名未报告癌症诊断(平均年龄 45 岁)的个体。我们考虑了几种患者报告的与睡眠相关的结果。使用多变量回归分析以及倾向评分匹配,以阐明睡眠障碍、处方助眠药物使用与癌症诊断之间的关系,按诊断后时间和主要疾病部位进行分层。
癌症幸存者中报告的睡眠障碍很常见,约有 34%的有癌症病史的患者报告曾经被告知他们有睡眠困难,而普通人群中没有癌症病史的患者比例为 23%(p<0.001)。倾向评分匹配支持癌症幸存者中睡眠困难的发生率明显高于匹配对照组。与没有癌症的普通成年人群相比,癌症幸存者在诊断 11 年或更长时间后更有可能报告被诊断为睡眠困难或睡眠障碍。此外,与没有癌症病史的成年人相比,患有妇科癌症的患者更有可能报告使用处方助眠药物、睡眠障碍和睡眠困难。
睡眠问题在癌症幸存者人群中很常见,尤其是在具有较长生存史和妇科癌症病史的患者中。考虑失眠和睡眠障碍的症状可能有助于这些患者的随访护理。